2021
DOI: 10.15585/mmwr.mm7033a3
|View full text |Cite
|
Sign up to set email alerts
|

Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities — Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020–March 1, 2021

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 5 publications
(3 reference statements)
0
6
0
Order By: Relevance
“…The RCATs are used to help inform patients if isolation is necessary due to SARS-CoV-2 infection. The demand for RCATs in the United States is highest during the holidays, when people use the assays to test themselves prior to seeing their friends and family members ( 10 ). Thus, it was reassuring to see that most of the tests we investigated still had high specificity and were sensitive enough to detect positive cases with C T values lower than 25, which is associated with viral shedding.…”
Section: Discussionmentioning
confidence: 99%
“…The RCATs are used to help inform patients if isolation is necessary due to SARS-CoV-2 infection. The demand for RCATs in the United States is highest during the holidays, when people use the assays to test themselves prior to seeing their friends and family members ( 10 ). Thus, it was reassuring to see that most of the tests we investigated still had high specificity and were sensitive enough to detect positive cases with C T values lower than 25, which is associated with viral shedding.…”
Section: Discussionmentioning
confidence: 99%
“…To that end, here, we report our objective assessment of Abbott's BinaxNOW COVID-19 Antigen Self-Test, which has among the highest usage, availability, distribution, and production rates of rapid tests and was the first lateral flow assay (LFA)-based rapid antigen test to receive U.S. FDA Emergency Use Authorization (EUA) for the home OTC setting (Shah et al, 2021a;Prince-Guerra, 2021;Pollock et al, 2021;Hodges, 2021). BinaxNOW is a SARS-CoV-2 diagnostic assay that detects the viral nucleocapsid (N) protein in samples collected by anterior nasal swab and reports a qualitative positive, negative, or invalid result (BINAXNOW COVID-19 AG CARD, n,d).…”
Section: Introductionmentioning
confidence: 99%
“…Third, the analytic design did not allow for the consideration of the role of undetected previous SARS-CoV-2 infection as an additional protective factor over the course of the study period. However, robust SARS-CoV-2 testing was widely available in this population throughout the study period, and results were reported routinely to the regional health system [ 19 ]. Fourth, participation in routine screening might also affect the relative rate ratios.…”
Section: Discussionmentioning
confidence: 99%